Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies

Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies

Background. Rivaroxaban and apixaban are the most widely used nonvitamin K oral anticoagulants (NOACs) in patients with venous thromboembolism (VTE). This meta-analysis evaluates the effectiveness and safety of both NOACs versus standard of care (SoC) in real-world practice. Methods. Real-world evid...

Full description

Saved in:

Bibliographic Details
Main Authors:	Olivia Wu, Stephen Morris, Torben Bjerregaard Larsen, Flemming Skjøth, Alex Evans, Kevin Bowrin, Piotr Wojciechowski, Wojciech Margas, Maria Huelsebeck
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Series:	Cardiovascular Therapeutics
Online Access:	http://dx.doi.org/10.1155/2022/2756682
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
by: Mette Søgaard, et al.
Published: (2019-03-01)

Cost-Consequence Analysis of Apixaban Versus Rivaroxaban for Managing Patients with Venous Thromboembolism in Saudi Arabia
by: Abdulaali R. Almutairi PhD, et al.
Published: (2025-02-01)

Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants
by: Mariacarla Gallù, et al.
Published: (2020-01-01)

Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism
by: Marte Svalastoga, et al.
Published: (2025-01-01)

SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) WITH LOW DOSE APIXABAN OR RIVAROXABAN: RESULTS FROM A PATIENT POPULATION WITH MORE THAN 2 YEARS OF MEDIAN FOLLOW-UP
by: Alessandro Laganà, et al.
Published: (2024-02-01)

Current Status of New Anticoagulants in the Management of Venous Thromboembolism
by: Roberto C. Montoya, et al.
Published: (2012-01-01)

Reduced versus full apixaban lead-in dosing following parenteral treatment of acute venous thromboembolism
by: Daniella Veloria, et al.
Published: (2025-03-01)

Aftermath of Apixaban: Atypical Anticoagulation Aftereffect
by: Bhesh Karki, et al.
Published: (2022-01-01)

Global Research Hotspots in Venous Thromboembolism Anticoagulation: A Knowledge-Map Analysis from 2012 to 2021
by: Jia Wang, et al.
Published: (2023-01-01)

Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment
by: Thomas Wilke, et al.
Published: (2019-01-01)

Direct oral anticoagulants versus warfarin for venous thromboembolism prophylaxis in nephrotic syndrome patients: a retrospective study
by: Ahmed El-Bardissy, et al.
Published: (2025-01-01)

Recurrence of LV Thrombus in a Patient with Severe Ischaemic Cardiomyopathy Anticoagulated with Apixaban
by: Azhar Farooqui, et al.
Published: (2022-01-01)

Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain
by: Xavier Granero Xiberta, et al.
Published: (2016-01-01)

Comment on: Multimorbidity, comorbidity, frailty, and venous thromboembolism
by: Maria I. Zervou, et al.
Published: (2025-02-01)

PERIOPERATIVE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ROUTINE ONCOSURGERY
by: V. E. Khoronenko, et al.
Published: (2016-12-01)

Venous thromboembolism still leads on maternal death
by: Amelia Shard, et al.
Published: (2025-01-01)

Response to Comment on: Multimorbidity, comorbidity, frailty, and venous thromboembolism
by: Bengt Zöller, et al.
Published: (2025-02-01)

Strategies for Diagnosis and Prevention of Venous Thromboembolism during Pregnancy
by: Shalini Jain Bagaria, et al.
Published: (2011-01-01)

Successful Treatment and Secondary Prevention of Venous Thrombosis Secondary to Behçet Disease with Rivaroxaban
by: Ana Boban, et al.
Published: (2016-01-01)

Causal relationship between educational attainment and the occurrence of venous thromboembolism
by: Sitong Guo, et al.
Published: (2025-02-01)

Racial disparities in extended venous thromboembolism prophylaxis after hysterectomy.
by: Wenbo Wu, et al.
Published: (2025-01-01)

Biological Aging and Venous Thromboembolism: A Review of Telomeres and Beyond
by: Rafaela Vostatek, et al.
Published: (2024-12-01)

Spontaneous Adrenal Hemorrhage with Mild Hypoadrenalism in a Patient Anticoagulated with Apixaban for Antiphospholipid Syndrome: A Case Report and Literature Review
by: Jia Wei Tan, et al.
Published: (2022-01-01)

Case Report of a Massive Thigh Hematoma after Adductor Canal Block in a Morbidly Obese Woman Anticoagulated with Apixaban
by: Katherine L. Koniuch, et al.
Published: (2018-01-01)

Venous thromboembolism in bullous pemphigoid: current evidence and update on systematic review
by: Atheer G. Almutairi, et al.
Published: (2025-01-01)

Risk of postoperative bleeding and thromboembolic events in anticoagulated patients undergoing transurethral resection of bladder tumors
by: Thomas Paul Scherer, et al.
Published: (2025-02-01)

Managing a Rivaroxaban Bleed: Understanding the Difficulties in Acute Reversal of the New Oral Anticoagulants through a Case Report
by: Naveen Nannapaneni, et al.
Published: (2014-01-01)

Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
by: Yachar Dawudi, et al.
Published: (2025-01-01)

Multimorbidity is associated with risk of incident venous thromboembolism – A nationwide proof-of-concept study
by: Jonatan Ahrén, et al.
Published: (2025-03-01)

Risk of Venous Thromboembolism in Patients Nursed at Home or in Long-Term Care Residential Facilities
by: Guido Arpaia, et al.
Published: (2011-01-01)

Circulating, Extracellular Vesicle-Associated Tissue Factor in Cancer Patients with and without Venous Thromboembolism
by: Valentina Lami, et al.
Published: (2025-01-01)

Evaluation of Risk Factors of Venous Thromboembolism in Imam Sadiq Teaching Hospital at Babylon City
by: Intisar Mahdi Kadhim Almurshedi, et al.
Published: (2022-11-01)

Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database
by: Gregory Y H Lip, et al.
Published: (2012-12-01)

Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case–control analyses from UK primary care
by: Luis Alberto García Rodríguez, et al.
Published: (2022-06-01)

Risk factors for venous thromboembolism after hip arthroscopy: a systematic review and meta-analysis
by: Haoxuan Li, et al.
Published: (2025-02-01)

Frequency and treatment of venous thromboembolic events in patients with space-occupying brain infarction and decompressive craniectomy
by: Dominik Michalski, et al.

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
by: Raffaele De Caterina, et al.
Published: (2019-03-01)

Large Left Ventricular Thrombus in a Patient with Systemic and Venous Thromboembolism Secondary to Protein C and S Deficiency
by: Mohit Pahuja, et al.
Published: (2017-01-01)

Investigating the dual causative pathways linking immune cells and venous thromboembolism via Mendelian randomization analysis
by: Ning Qi, et al.
Published: (2025-01-01)

Incidence, Risk Factors, and Modified Risk Assessment Model of Venous Thromboembolism in Non‐Hodgkin Lymphoma Patients
by: Wen Li, et al.
Published: (2024-12-01)